First publication of clinical efficacy data for PP353, in development for chronic Low Back PainTrial demonstrated that PP353 delivers clinically ...
The PP353 clinical trial met the primary endpoint and demonstrated statistically significant, clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain ...
Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025 Persica is developing PP353, a potentially curative, opioid-sparing ...
HOUSTON--(BUSINESS WIRE)--Degenerative disc disease has long been considered an inevitable part of aging, but new breakthrough research from SpinalCyte, LLC, a Texas-based regenerative medicine ...
Please provide your email address to receive an email when new articles are posted on . Intradiscal oxygen-ozone chemonucleolysis met non-inferiority criteria and achieved similar rapid, significant ...
Allogeneic bone marrow–derived mesenchymal stromal cells (BM-MSCs) are safe but do not show efficacy in treating intervertebral disc degeneration (IDD) in patients with chronic low back pain. The ...
Oxygen-ozone therapy represents a minimally invasive clinical approach that aims to alleviate low back pain associated with disc herniation. The treatment involves the percutaneous administration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results